Note : Support and Resistance level for the month, calculated based on price range of the previous trading month.

However, there is no assurance that the objective of the scheme will be realized. The Kotak Equity Hybrid Direct Growth has an AUM of 6913.47 crores & has delivered CAGR of 17.91% in the last 5 years.

There is no assurance that the investment objective of the scheme will be achieved. The Kotak Emerging Equity Scheme Growth has an AUM of 53078.98 crores & has delivered CAGR of 23.22% in the last ...

Fund manager updated portfolio more frequently than peers in last 1 year. (I.e. fund manager held stocks/bonds in the portfolio for shorter duration than peers) ...

The average amount, 4,800 micrograms per gram of microplastics in brain tissue, was found to be equivalent to the amount found in a standard plastic spoon, according to the study. MORE ...

Exploring innovative solutions to improve the healthcare of the aging and diseased population continues to be a global challenge. Among a number of strategies toward this goal, tissue engineering and ...

Tissue engineering is a set of methods that can replace or repair damaged or diseased tissues with natural, synthetic, or semisynthetic tissue mimics. These mimics can either be fully functional ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Connective tissue diseases are a heterogeneous group of autoimmune disorders that affect any of the body's connective tissues. These disorders can be inherited or acquired, and can present with a ...

1. Current NAV: The Current Net Asset Value of the Kotak Flexicap Fund - Regular Plan as of Feb 04, 2025 is Rs 77.36 for Growth option of its Regular plan. 2. Returns: Its trailing returns over ...

1. Current NAV: The Current Net Asset Value of the Kotak Focused Equity Fund - Regular Plan as of Feb 07, 2025 is Rs 23.19 for Growth option of its Regular plan. 2. Returns: Its trailing returns over ...

Kotak Institutional Equities in a fresh note said opportunities outside pure-play ERD companies are more attractive in the near term. It maintained its 'Sell' ratings on KPIT Technologies Ltd, L&T ...